NASDAQ: ANABAnaptysbio Inc Stock
$16.73-0.11 (-0.65%)
Updated Mar 14, 2025
ANAB Price
$16.73
Fair Value Price
N/A
Market Cap
$513.06M
52 Week Low
$12.21
52 Week High
$41.31
P/E
-3.27x
P/B
7.24x
P/S
4.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$91.28M
Earnings
-$145.23M
Gross Margin
100%
Operating Margin
-159.1%
Profit Margin
-159.1%
Debt to Equity
5.83
Operating Cash Flow
-$135M
Beta
0.89
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ANAB Overview
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ANAB's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ANAB
Ranked#118 of 484
Ranked#118 of 484
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.84 | A | |
| $137.96 | A | |
| $8.16 | A |
Be the first to know about important ANAB news, forecast changes, insider trades & much more!
ANAB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ANAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ANAB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ANAB is poor value based on its book value relative to its share price (7.24x), compared to the US Biotechnology industry average (4.68x)
P/B vs Industry Valuation
ANAB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ANAB due diligence checks available for Premium users.
Valuation
ANAB fair value
Fair Value of ANAB stock based on Discounted Cash Flow (DCF)
Price
$16.73
Fair Value
-$14.04
Undervalued by
219.15%
ANAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ANAB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.27x
Industry
-118.09x
Market
3,446.61x
ANAB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.24x
Industry
4.68x
ANAB is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ANAB's financial health
Profit margin
Revenue
$43.1M
Net Income
-$21.8M
Profit Margin
-50.5%
ANAB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ANAB's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$483.8M
Liabilities
$413.0M
Debt to equity
5.83
ANAB's short-term assets ($431.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANAB's short-term assets ($431.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANAB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ANAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$66.7M
Investing
-$29.4M
Financing
$27.6M
ANAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ANAB vs Biotech Stocks
Anaptysbio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.